reSET-O

Novartis is cutting off its digital therapeutics commercialization partnership with Pear Therapeutics
By Dave Muoio | 11:28 am | October 16, 2019
The pharma's Sandoz division will be handing commercialization of reSET, reSET-O and future therapies back to Pear over the course of a transition period.
Digital therapeutics get first FDA clearance, Novartis focuses on digital after announcing job cuts and other Q4 pharma news
By MobiHealthNews | 12:25 pm | December 26, 2018
Also: The pharma industry continues to use digital technologies for R&D and diabetes management. 
Pear's digital therapeutic reSET-O FDA cleared to treat opioid use disorder
By Laura Lovett | 06:37 pm | December 10, 2018
The prescription digital therapeutic will give users interactive therapy lessons to be use by patients under a clinician's supervision.